Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 14/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3305703 | 1.00 | CYP3A4 (0.39) | CYP3A4MAPTKDM4EALDH1A1KMT2A | |
| SCHEMBL3306913 | 0.86 | CHRM2 (0.44) | CYP3A4MAPTKDM4EALDH1A1 | |
| SCHEMBL3303203 | 0.86 | CHRM2 (0.44) | CYP3A4MAPTKDM4EALDH1A1 | |
| SCHEMBL3301760 | 0.86 | CHRM2 (0.44) | CYP3A4MAPTKDM4EALDH1A1 | |
| SCHEMBL6328311 | 0.85 | NR1H2 (0.34) | CYP3A4KDM4EHCRTR2ACE | |
| SCHEMBL6608199 | 0.84 | HCRTR2 (0.31) | CYP3A4KDM4EHCRTR2ACE | |
| SCHEMBL6328315 | 0.84 | HCRTR2 (0.32) | CYP3A4MAPTHCRTR2ACE | |
| SCHEMBL6334750 | 0.84 | HCRTR2 (0.31) | CYP3A4KDM4EHCRTR2ACE | |
| SCHEMBL3303118 | 0.83 | HCRTR2 (0.39) | HCRTR2ACE | |
| SCHEMBL3303603 | 0.79 | ACE (0.32) | HCRTR2ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100094014-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | MARTINEZ-PEREZ JOSE ANTONIO | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100094014-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | SLC1A2, SLC1A1, GRIN1 | CYP3A4 3872/4885MAPT 631/4885KDM4E 3336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.